Key Takeaways
- Record year, powered by one molecule: FY25 revenue jumped 45% YoY to ₹1,030 crore and PAT nearly doubled, driven by a cardiovascular intermediate that scaled more than 4x and now anchors the PI/API segment.
- Contrast media is the drag that matters: The segment degrew 15.8% for the full year, and the FY23 ₹500 crore peak was an outlier stocking event, not a base to measure against; real uptick waits on new molecule commercialization and capacity adds.
- Capacity build is aggressive and multi-site: 157 KL added at Ambernath, a GMP multipurpose plant at Mahad on track for H2 FY27, and a new Dahej site acquired, with CAPEX guidance raised to ~₹300 crore plus.
- The fund-raise question is live but opaque: A ₹1,500 crore raise has been decided, likely tied to the Dahej plant, but management declined to share any details, promising visibility in the immediate quarter.
- What to watch next quarter: Details on the fund-raise structure and purpose, the pace of iodinated contrast intermediate commercialization in H1 FY26, and whether the cardiovascular intermediate’s prescription growth sustains above 60%.
The Cardiovascular Intermediate: The Quarter’s Engine
- Scale-up drove the P&L: The PI/API segment grew more than 4x YoY, with the cardiovascular intermediate reaching decent capacity utilization by Q4 and customer offtake tracking well into FY26.
- Demand tailwind is structural: Prescriptions grew over 60% in the last calendar year after a label update made the molecule a primary line of treatment, expanding the addressable market 7x; growth is now faster in Europe and Latin America than in the US.
- Patent protection extended: Esperion settled with some generic companies to block entry until 2040, indirectly prolonging the molecule’s life.
- Supply chain is dual-customer: The product reaches the European market through Daiichi, and management says regulatory barriers and contracts protect the relationship, though it declined to confirm a signed contract with Daiichi when pressed.
- Capacity math is tight: Per an analyst’s math, Q4 utilization may have been close to 100%; management called it good arithmetic but did not confirm, noting only that full-year utilization was 60-65%.
VK Singh: "Today, there are 9,000 cardiologists in the US who are prescribing this and this has become the primary line of treatment. Earlier it was the secondary line of treatment. Because of the label update and label expansion, both in the US and Europe, I think the addressable market of this has grown 7x of what it used to be."
Contrast Media: Stabilizing, Not Yet Growing
- FY25 was a reset year: The segment degrew 15.8%, hit by a slowdown in offtake in Q1 and goods in transit in Q4; the FY23 ₹500 crore figure was an outlier driven by a customer security-stock build, and ₹400 crore is the base business.
- New molecules are the growth path: An NCE molecule (gadopiclenol) began commercial sales in Q4 and is expected to grow linearly as it finds its market; iodinated intermediate commercialization is expected in H1 FY26 with full potential in FY27.
- Capacity is a moving target: Management declined to stipulate peak revenue because capacity is added every six months; the company has quadrupled contrast media capacity in the past few years.
Capacity Expansion: The Multi-Year Buildout
- Ambernath Unit-2 now live: 157 KL of new capacity commissioned across two phases, with the new CDMO block in commercial production and running at 60-65% utilization on consistent schedules backed by high order visibility.
- Mahad Unit-3 is the next milestone: A continuous-process plant for feedstock and derivatives, with GMP-compliant finished-product capability including two clean rooms and particle sizing; designed to be USFDA-approvable, with the approval trigger an option to exercise with a client. On stream H2 FY27.
- Mahad MPP adds versatility: A ~30-reactor GMP multipurpose plant with dedicated milling, single-fluid-system reactors for proof-of-concept and validation, and capability from kilos to multi-tons; this drove the CAPEX increase from ~₹250 crore to ~₹300 crore. On stream H2 FY27.
- Dahej is the long bet: Land acquired in GIDC Dahej with DC approval in place; a larger plant is planned, likely tied to the QIP, but no firm timelines shared as allotment is very recent.
- No bottleneck for two years: Current 75% overall utilization excludes Mahad capacity; management sees no capacity constraint for the next two years, with immediate opportunities served from existing multipurpose plants.
VK Singh: "We have two types of growth in our business. One is the secular growth that we get because the market is growing. The second is each time we forward integrate that we give a more advanced intermediate. Sometimes the value is, 2x-3x from the same capacity."
Margins, Costs & Working Capital
- Margin expansion was real: EBITDA margin improved from 32% to 37%, with gross margins stable at 55%; freight and power costs were well optimized, and the cardiovascular intermediate’s ex-works terms reduced ocean freight exposure.
- Other expenses reset lower: QoQ decline in other expenses was driven by the shift to ex-works supply for the cardiovascular intermediate; with PI/API and contrast media now at equal weight, this lower OPEX norm is expected to persist.
- Cash conversion stretched on growth: The cash cycle lengthened to 139 days from 135, with working capital up ~₹250 crore to support the 388% growth in PI/API; management expects to operate within this cycle until the next step-up in turnover.
- No margin guidance given: When asked about steady-state margin ramp-up from operating leverage, management declined to guide, stating only that the business operates in highly demand-inelastic markets.
Pipeline, R&D & New Opportunities
- R&D center committed: ₹40 crore allocated for a new R&D center focused on amino acid derivatives, advanced intermediates, and late-stage NCE intermediates, with newer chemistry platforms like peptides, GLP-1 intermediates, and immobilized biocatalysts.
- Pipeline is deep and late-stage heavy: Tracking ~20 new opportunities with high client interest; about 30% are in late Phase 3 or commercial.
- GLP-1 opportunity is real but unquantified: Management called the overall opportunity size considerably large but declined to comment on whether it could match the cardiovascular intermediate or whether Blue Jet would work directly with the innovator.
- CDMO tailwinds are structural: Europe-based innovators are showing strong traction, supported by new business development hires; MNCs are derisking from China, driving a quantum increase in RFPs, and management believes these changes are structural and durable.
- Process excellence investment: ~₹60 crore committed for new solvent recovery units to reduce waste and encourage recycle and reuse.
Housekeeping & Risks
- Income tax notice of ₹200 crore: The company is comfortable with its stand and will wait for the appeal process.
- Innovator supply risk unaddressed: When asked how wallet share is protected if the innovator adds other sources for the cardiovascular intermediate, management said it goes by customer forecasts, does not speculate on news articles, and believes it is in the innovator’s good books, without directly addressing the risk.
- Debt-free and dividend declared: The company remains debt-free and declared a dividend of ₹1.20 per share, subject to shareholder approval.
Shiven Arora: "Even if they evaluate others, I think that is what Ganesh mentioned."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Iodinated contrast intermediate commercialization | Commercial launch expected; full potential in FY27 | H1 FY26 |
| Mahad Unit-3 backward integration plant | Continuous-process plant for feedstock and derivatives, on stream | H2 FY26 |
| Mahad MPP (GMP, ~30 reactors) | Versatile plant with clean rooms, milling, single-fluid systems, on stream | H2 FY27 |
| Fund-raise details disclosed | More visibility on the ₹1,500 crore raise | Immediate quarter (Q1 FY26) |
| Baseline CAPEX (ex-Dahej, ex-new sites) | ~₹300 crore plus, up from ~₹200 crore earlier | FY26 |
| Capacity bottleneck | No bottleneck seen | Next two years |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Revenue (FY25) | ₹1,030 cr, +45% YoY |
| EBITDA (FY25) | ₹377.7 cr, margin of 37%, up 65% YoY |
| PAT (FY25) | ₹305.2 cr, up 87% YoY |
| EPS (FY25) | ₹17.59 per share, compared to ₹9.44 in FY24 |
| Q4 revenue growth | +6.9% QoQ |
| Q4 EBITDA growth | +12.9% QoQ |
| PI/API segment revenue growth (FY25) | +388% YoY |
| Contrast media segment revenue growth (FY25) | -15.8% YoY |
| Artificial sweeteners revenue (FY25) | ₹133 cr, +4.1% YoY |
| Artificial sweeteners gross margin (FY25) | 15.2%, flat YoY |
| Artificial sweeteners operational EBITDA margin (FY25) | 36.7%, up 4.4% YoY |
| Cash and treasury investments | ₹284.8 cr as on March 31, 2025 |
| Cash conversion cycle | 139 days, compared to 135 days in Q4 FY24 |
| Working capital increase | ~₹250 cr, one-time increase to support higher activity levels |
| Overall capacity utilization | ~75% across all segments |
| PI/API capacity utilization | 60–65% for FY25 |
| CWIP (FY25) | ₹89 cr |
| Fresh CAPEX planned (FY26) | ~₹300 cr, excluding new sites or Dahej |
| Unit-3 Mahad CAPEX | ~₹300 cr, increased from earlier plan of ~₹250 cr |
| Process excellence initiative CAPEX commitment | ~₹60 cr |
| R&D center CAPEX commitment | ₹40 cr |
| New capacity added (Unit-2 Ambernath) | 157 KL across two phases |
| Dividend declared | ₹1.20 per share, subject to shareholder approval |
| Pharma intermediate molecules tracked | 28 molecules, up from 22 in the previous quarter |
| Late-stage opportunities (phase 3 or commercial) | ~30% of 20 new opportunities being tracked |
| Cardiovascular intermediate Q4 revenue | ~₹200 cr |
| Cardiovascular molecule prescribers (US) | 9,000 cardiologists |
| Cardiovascular molecule addressable market expansion | 7x due to label expansion |
| De-bottlenecking potential (PI/API) | ~20% additional capacity, achievable in 8–9 weeks |
| Income tax notice | ₹200 cr, Company comfortable with its stand |